GlassScriptPhysician profile
Stephen Kopecky
NPI 1225008329
$29,768.07
in general payments reported to CMS, 2019-2025
8 companies · $8,683 in 2025
The $8,683 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,012 · 2020: $16K · 2021: $595 · 2024: $1,880 · 2025: $8,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,562.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,657.08 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $6,712.50 | 2024-2025 | |
| Roche Diabetes Care Gmbh | $3,000.00 | 2019 | |
| Madrigal Pharmaceuticals | $2,100.00 | 2025 | Rezdiffra |
| Sanofi US Services INC. | $1,750.00 | 2025 | |
| Merck Sharp & Dohme LLC | $500.00 | 2020 | |
| Akcea Therapeutics, INC. | $36.04 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kopecky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.